Our customers come to us to take advantage of our expertise in a wide range of therapeutic areas. We have the knowledge, experience and skills to ensure that your development pathway stays on track.
Our advanced knowledge and renewed technology are now being applied to research on neuropsychiatric disorders such as anxiety, sleep disorders, depression, schizophrenia, epilepsy, pain and drug-food addiction. In addition, we are also working on innovative solutions for neurodegenerative diseases such as Alzheimers, Huntingtons, Parkinsons and front-temporal dementia.
Our Antibacterial Discovery platform provides end-to-end solution from the very early phases (HTS screening by phenotypic screening) to the selection of the clinical candidates by applying translational-based modelling based on PK/PD readout, through bacterial target validation.
Our Oncology group offers a variety of multidisciplinary research solutions, including in vitro assays, tumour models (xenograft, orthotopic, metastatic) and associated biomarkers. These can be provided utilising a range of human tumor cells and syngenic murine models and imaging techniques (e.g. bioluminesce) can be applied to provide objective non-invasive readouts in longitudinal studies.
We have extensive knowledge and experience in the screens and models required to progress compounds through Respiratory Drug Discovery and Development. Our multi-disciplinary teams can work with you to design and carry out the most appropriate studies to progress your project(s).